Journal of Antimicrobial Chemotherapy (2002) 50, 43-50
© 2002 The British Society for Antimicrobial Chemotherapy
Streptococcus pneumoniae bacteraemia in Belgium: differential characteristics in children and the elderly population and implications for vaccine use
1 Department of Geriatric Medicine, 2 Department of Microbiology, 3 Department of General Internal Medicine, University Hospital Leuven, Leuven, Belgium
Received 22 January 2001; returned 24 September 2001; revised 28 March 2002; accepted 17 April 2002
The characteristics of bacteraemia with Streptococcus pneumoniae in children (0–4 years) and the elderly (
60 years) were compared over a 7 year period (1994–2000). Of a total of 7927 isolates of invasive S. pneumoniae studied in the national reference laboratory, 74% (n = 5837) were blood isolates. Of these 5837 S. pneumoniae bacteraemias, 843 (14%) occurred in children and 3144 (54%) in the elderly. The prevalence of penicillin resistance (MIC 0.1 mg/L) in bacteraemic isolates rose from 8.2% to 18.9% (P = 0.03) in children and from 5.1% to 16.35% (P = 0.001) in the elderly over the study period. The prevalence of erythromycin resistance (MIC 1 mg/L) in bacteraemic isolates was significantly higher in children than in the elderly (44.7% versus 25.7%, P = 0.001) and rose significantly over the 7 year period in the elderly (18.6–33.65%, P = 0.001). There were more serogroups and serotypes (SGTs) among the bacteraemic isolates obtained from the elderly compared with children (36 versus 26, P = 0.03). SGTs 6, 14, 18 and 19 cause significantly more bacteraemia in children than in the elderly. The opposite is true for SGTs 3, 7, 8, 9, 11, 12, 15, 20, 22 and 35. The new 7, 9 and 11 valent conjugate vaccine formulations cover significantly more bacteraemic SGTs in children than in the elderly (82%, 89.5% and 92% versus 55.5%, 65% and 77.5%, respectively; P = 0.001). The 23 valent polysaccharide vaccine provides a theoretical coverage of 95% in the elderly population. Our data indicate consideration of a vaccination strategy in the elderly population that combines the efficacy of conjugate vaccines with the broad coverage of the 23 valent polysaccharide vaccine.
* Corresponding author. Tel: +32-16-33-79-40; Fax: +32-16-33-79-41; E-mail: johan.flamaing{at}uz.kuleuven.ac.be
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Flamaing, J. Verhaegen, J. Vandeven, N. Verbiest, and W. E. Peetermans Pneumococcal bacteraemia in Belgium (1994 2004): the pre-conjugate vaccine era J. Antimicrob. Chemother., January 1, 2008; 61(1): 143 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vergison, D. Tuerlinckx, J. Verhaegen, A. Malfroot, and for the Belgian Invasive Pneumococcal Disease Stud Epidemiologic Features of Invasive Pneumococcal Disease in Belgian Children: Passive Surveillance Is Not Enough Pediatrics, September 1, 2006; 118(3): e801 - e809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dias, D. Louro, the Antimicrobial Resistance Surveillance Program, and M. Canica Antimicrobial Susceptibility of Invasive Streptococcus pneumoniae Isolates in Portugal over an 11-Year Period Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2098 - 2105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bogaert, P. van der Valk, R. Ramdin, M. Sluijter, E. Monninkhof, R. Hendrix, R. de Groot, and P. W. M. Hermans Host-Pathogen Interaction during Pneumococcal Infection in Patients with Chronic Obstructive Pulmonary Disease Infect. Immun., February 1, 2004; 72(2): 818 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-W. Decousser, P. Pina, F. Picot, C. Delalande, B. Pangon, P. Courvalin, P. Allouch, and the ColBVH study group Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey J. Antimicrob. Chemother., May 1, 2003; 51(5): 1213 - 1222. [Abstract] [Full Text] [PDF]
|
|